

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

### INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparin Pharmaceutical Group Co., Ltd. (the **Company**) regarding the bid for the acquisition of the **Group** (the **Inside Information**) pursuant to the provisions of Article 13.09(2)(a) of the Listing Rules (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Listing Rules (the **Listing Rules**).

The board of directors (the **Directors**) of the Company (the **Board**) in the interest of the shareholders of the Company (the **Shareholders**) and the interests of Techdow Pharma Italia S.R.L., a wholly owned subsidiary of the Company (the **Techdow Italy**), in accordance with the best interests of the Company and the shareholders of the Company, have decided to file a declaration of interest in the Company (the **Incident**). The Company has decided to file a declaration of interest in the Company. The declaration has been filed with the relevant authorities in accordance with the applicable laws and regulations. The Company has decided to file a declaration of interest in the Company. The declaration has been filed with the relevant authorities in accordance with the applicable laws and regulations.

The management of the Company has decided to file a declaration of interest in the Company. The declaration has been filed with the relevant authorities in accordance with the applicable laws and regulations. The Company has decided to file a declaration of interest in the Company. The declaration has been filed with the relevant authorities in accordance with the applicable laws and regulations.

The independent members of the Company's Board of Directors, including the independent non-executive directors, have reviewed the financial statements of the Company for the period ended 31 December 2023 (FY2023).

The Company's independent non-executive directors have reviewed the financial statements of the Company for the period ended 31 December 2023 (FY2023).

The Board has approved the financial statements of the Company for the period ended 31 December 2023 (FY2023).

The Company will make the annual general meeting of the Company to discuss the financial statements of the Company for the period ended 31 December 2023 (FY2023) (Annual Results), which is expected to be held in March 2024, in accordance with the Listing Rules, and the financial statements of the Company for the period ended 31 December 2023 (FY2023).

**Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
January 15, 2024

*As a reminder of his announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Y. and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. L. Chan, Mr. Hang Peng and Mr. Yi Ming.*